Genitourinary Cancer

Vicineum Granted Priority Review for High-Risk, BCG-Unresponsive Bladder Cancer

February 18, 2021

The FDA has accepted and granted a priority review designation to the biologics license application for Vicineum for use in patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Shorter SBRT Treatment Is Safe, Efficacious in High-Risk Prostate Cancer

January 28, 2021

A shorter course of stereotactic body radiotherapy (SBRT) has been shown to have encouraging efficacy with favorable toxicity when used in patients with high-risk prostate cancer in a multi-institutional, international setting, according to findings from a study published in the International Journal of Radiation Oncology, Biology, Physics.

Padeliporfin ImPACT Granted Fast Track Status for Upper-Tract Urothelial Cancer

January 19, 2021

The FDA has granted a fast track designation to padeliporfin Immune Photo Activated Cancer Therapy (ImPACT) for use in the treatment of patients with low-grade and unifocal upper-tract urothelial cancer (UTUC), according to an announcement from Steba Biotech.